Oncternal gains on approval to start blood cancer therapy trial

Oncternal Therapeutics

04/10/2022 17:04

** Drug developer Oncternal Therapeutics Inc's  ONCT.O 
shares rise 13.3% to $1.1, their biggest one-day pct gain in
nearly four months at current levels
    ** U.S. FDA approves application to initiate early-stage
clinical trial for therapy to treat patients with aggressive B
cell non-Hodgkin's lymphoma  urn:newsml:reuters.com:*:nGNX2Ywrf7
    ** Aggressive B cell non-Hodgkin's lymphoma is a high-grade
cancer that advances much faster than indolent, low-grade
tumors, and is present in the lymph nodes
    ** Including session gains, stock lost ~52% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))